NCT05719376View on ClinicalTrials.gov

The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Kidney Failure, Chronic
Interventions
DRUG

Monofer (experimental)

Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day

DRUG

control group

Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER